• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·JNJ
Held by 3 Gurus
Share

Johnson & Johnson Stocks

$ 263.81Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

$ 635.98B

$ 263.81
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.7%

Change

-0.07%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.6%

Change

+0.43%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.3%

Change

-0.06%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.7%-0.07%
Steven CohenPoint72 Asset Management, L.P.0.6%+0.43%
Kenneth GriffinCITADEL ADVISORS LLC0.3%-0.06%

Latest news

09.10.2026 15:00

TRex Bio IPO: LLY-backed biotech focused on autoimmune, inflammatory diseases debuts

14.09.2026 15:14

Morning in New York: Oil and AI Are Putting More Pressure on Stocks

03.07.2026 01:26

Dow Hits Record High, Chipmakers See Sell-Off: Investors Return to Old Economy Stocks

17.02.2026 14:15

Microsoft and Amazon stocks have lost nearly $1 trillion in capitalization. Where are investors going?

19.01.2026 13:15

Davos, inflation, Netflix and Intel: what investors need to know this week

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'ex

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of JNJ is 295 and suggests 11.8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026